Postpartum Depression Market Insight, Epidemiology And Market Forecast -2030

Postpartum Depression Market Insight, Epidemiology And Market Forecast -2030

“DelveInsight Business Research LLP”
DelveInsight’s ‘Postpartum Depression Market’ report delivers an in-depth understanding of the Postpartum Depression (PPD), historical and forecasted epidemiology as well as the Postpartum Depression (PPD) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Postpartum Depression Market

The Postpartum Depression market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM Postpartum Depression (PPD) market size from 2017 to 2030. The report also covers current Postpartum Depression (PPD) treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Postpartum Depression (PPD) Market Outlook

According to the American Psychiatric Association (APA), Postpartum depression (PPD) is a serious, but treatable medical illness, which involves feelings of extreme sadness, emotional liability, indifference and/or anxiety, as well as changes in energy, sleep, and appetite, and carries risks for the mother and the newborn child. PPD usually starts within the first month or any time within the first year after childbirth and can last from weeks to months. In more severe cases, it can develop into chronic episodes of depression.

Treatments include the antidepressant medications along with the new upcoming therapeutic strategies that work on the principle of GABAA receptor modulation. The medical management for PPD comprises several aspects such as interventions for depression, anxiety disorders, alcohol and drug abuse, and psychological interventions for eating disorders. The treatment strategy also encompasses psychological and psychosocial treatments, as well as non-pharmacologic treatments. Besides, the medical care of a PDD patient and his family is incomplete without providing a support system for their psychosocial wellbeing. The current US market consists of only one approved product—Zulresso (brexanolone/SAGE-547)—to treat patients with PPD.

Zulresso, which is marketed by Sage Therapeutics, was approved by the US FDA, in March 2019.

The PPD market outlook of the report helps to build a detailed comprehension of the historic, current and forecasted PPD market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers, and demand of better technology.

This segment gives a thorough detail of PPD market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, PPD 7MM market is expected to change in the study period 2018–2030.

Key Findings

This section includes a glimpse of the Postpartum Depression (PPD) 7MM market.

  • The market size of Postpartum Depression (PPD) in the United States was USD 42 million in 2020, which is expected to increase at a CAGR of 30.35% for the study period (2018–2030). Considering the best case scenario and based on KOL views, DelveInsight has done internal benchmarking, by considering considered all the assumptions on the higher end due to an optimistic approach during the forecast period.
  • Currently, the US market for PPD is dominated by the use of Selective serotonin reuptake inhibitors (SSRIs) only, Serotonin nonepinephrine reuptake inhibitors (SRNIs) only, Atypical antidepressants and Antipsychotics only, Combination therapies (SSRIs and atypical antidepressants, SSRI and other AD, SSRI and SNRI, SSRI and AP etc.) and Others (tetracyclines, modified cyclines, tricyclic agents, other ketamine derivatives etc.). Moreover, Zulresso (Brexanolone) was lanunched in March 2019 for the treatment of PPD.

Table of contents

1. Key Insight

2. Postpartum depression (PPD) Market Overview at a Glance

2.1. Market Share (%) Distribution of Postpartum depression (PPD) in 2017

2.2. Market Share (%) Distribution of Postpartum depression (PPD) in 2030

3. Disease Background and Overview: Postpartum depression (PPD)

3.1. Introduction

3.2. Clinical Presentation

3.3. Risk Factors

3.4. Pathogenesis

3.5. Diagnosis and Screening

3.5.1. Diagnostic Criteria

4. Epidemiology and Patient Population

4.1. Key Findings

4.2. 7MM Total Diagnosed Prevalent Population of Postpartum Depression (PPD)

5. Country-Wise Epidemiology of Postpartum Depression (PPD)

5.1. United States

5.1.1. Assumptions and Rationale

5.1.2. Total Diagnosed Prevalent Population of Maternal Postpartum Depression in the United States

5.1.3. Type-specific Diagnosed Prevalence of Postpartum Depression in the United States

5.2. EU5 Countries

5.3. Germany

5.3.1. Assumptions and Rationale

5.3.2. Total Diagnosed Prevalent Population of Maternal Postpartum Depression in Germany

5.3.3. Type-specific Diagnosed Prevalence of Postpartum Depression in Germany

5.4. France

5.4.1. Assumptions and Rationale

5.4.2. Total Diagnosed Prevalent Population of Maternal Postpartum Depression in France

5.4.3. Type-specific Diagnosed Prevalence of Postpartum Depression in France

5.5. Italy

5.5.1. Assumptions and Rationale

5.5.2. Total Diagnosed Prevalent Population of Maternal Postpartum Depression in Italy

5.5.3. Type-specific Diagnosed Prevalence of Postpartum Depression in Italy

5.6. Spain

5.6.1. Assumptions and Rationale

5.6.2. Total Diagnosed Prevalent Population of Maternal Postpartum Depression in Spain

5.6.3. Type-specific Diagnosed Prevalence of Postpartum Depression in Spain

5.7. United Kingdom

5.7.1. Assumptions and Rationale

5.7.2. Total Diagnosed Prevalent Population of Maternal Postpartum Depression in the United Kingdom

5.7.3. Type-specific Diagnosed Prevalence of Postpartum Depression in the United Kingdom

5.8. Japan

5.8.1. Assumptions and Rationale

5.8.2. Total Diagnosed Prevalent Population of Maternal Postpartum Depression in Japan

5.8.3. Type-specific Diagnosed Prevalence of Postpartum Depression in Japan

6. Treatment

6.1. Antidepressant medication

6.2. Psychological and psychosocial treatments

6.3. Non-pharmacologic treatments

6.4. Hormone therapy

7. Treatment Algorithm by American Family Physician (AFP)

8. Treatment Guidelines by Unicare

9. Treatment Guidelines by the National Institute for Health and Care Excellence (NICE)

10. Recognized Establishments

11. Unmet Needs

12. Marketed Profile

12.1. Zulresso (brexanolone): Sage Therapeutics

12.1.1. Drug Description

12.1.2. Regulatory Milestones

12.1.3. Other Development Activities

12.1.4. Safety and Efficacy

12.1.5. Product Profile

12.2. Emerging Drugs

12.3. Key Cross Competition

12.4. Zuranolone (SAGE-217): Sage Therapeutics

12.4.1. Drug Description

12.4.2. Other Developmental Activities

12.4.3. Clinical Development

12.4.4. Safety and Efficacy

12.4.5. Product Profile

12.5. Ganaxolone (CCD-1042): Marinus Pharmaceuticals

12.5.1. Product Description

12.5.2. Other Developmental Activities

12.5.3. Clinical Development

12.5.4. Safety and Efficacy

12.5.5. Product Profile

13. Postpartum Depression: 7 Major Market Analysis

13.1. Key Findings

13.2. Market Size of Postpartum Depression in the 7MM

14. The United States Market Outlook

14.1. United States Market Size

14.1.1. Total Market size of Postpartum Depression

14.1.2. Market Size by Therapies

14.2. EU-5 Countries: Market Outlook

14.2.1. Germany

14.2.1.1. Total Market size of Postpartum Depression

14.2.1.2. Market Size by Therapies

14.2.2. France

14.2.2.1. Total Market Size of Postpartum Depression

14.2.2.2. Market Size by Therapies

14.2.3. Italy

14.2.3.1. Total Market Size of Postpartum Depression

14.2.3.2. Market Size by Therapies

14.2.4. Spain

14.2.4.1. Total Market Size of Postpartum Depression

14.2.4.2. Market Size by Therapies

14.2.5 United Kingdom

14.2.5.1. Total Market Size of Postpartum Depression

14.2.5.2. Market Size by Therapies

15. Japan: Market Outlook

15.1. Japan market Size

15.1.1. Total Market Size of Postpartum Depression

15.1.2. Market Size by Therapies

16. KOL Reviews

17. Case Reports

17.1. Patient Story: Postpartum Depression (American Psychiatric Association)

17.2. Case Study: The Effectiveness of Kangaroo Care for a Patient with Postpartum Depression and Comorbid Mother-Infant Bonding Disorder

18. Market Drivers

19. Market Barriers

20. SWOT Analysis

21. Appendix

21.1. Bibliography

21.2. Report Methodology

22. DelveInsight Capabilities

23. Disclaimer

24. About DelveInsight

Request for sample pages @ Postpartum Depression Market Size 

Media Contact
Company Name: DelveInsight
Contact Person: Priya Maurya
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/